A Phase 4 interventional study of G-CSF and Antibiotics only in Febrile Neutropenia, Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy and Febrile Neutropenia, Drug-Induced, sponsored by King Edward Medical University. Not yet recruiting. Open to participants aged 1 Year to 16 Years. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by King Edward Medical University · Phase 4, Interventional, and Treatment
This study aim to find the best option for children having cancer who develop low immunity state due to chemotherapy
Children having a cancer diagnosis and treated with chemotherapy often develop neutropenia. This creates an immunocompromised state which can result in infections manifested by fever. This study compares two treatment options to find out the best treatment for these patients.
147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.
This study's planned enrollment of 150 is above the median of 120 across 95 interventional studies indexed under Febrile Neutropenia.
Browse Febrile Neutropenia studies →King Edward Medical University is the lead sponsor of 84 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
G-CSF plus antibiotic therapy
Drug: G-CSF
Antibiotic Therapy
Drug: Antibiotics only
G-CSF \& Antibiotic therapy in combination
Antibiotics alone
Resolution of FN
Duration of resolution of febrile neutropenia (in days)
Time frame: 2 weeks
Afebrile
Duration of resolution of fever (in days)
Time frame: 2 weeks
Length of hospital stay
Length of hospital stay (in days)
Time frame: 2 weeks
No study locations are listed for this record.
Plan to share: Yes — Data dictionary will be made available on request
Supporting information: Study protocol
No publications or documents are linked to this record.
Start is estimated for Jun 2025; primary completion for May 2026, 11 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Granulocyte Colony-Stimulating Factor
King Edward Medical University